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Introduction
Unlike protein kinases, mutations in serine/threonine (Ser/Thr) 
protein phosphatases have not commonly been associated with 
disorders of human development. There are 2 major Ser/Thr 
protein phosphatase families in the cell: protein phosphatase 1 
(PP1) and protein phosphatase 2A (PP2A), together accounting 
for more than 90% of all phospho-Ser/Thr dephosphorylations. 
PP2A consists of a catalytic subunit (C), a substrate binding regu-
latory subunit (B), and a scaffolding subunit (A) that links B and C. 
Unlike the generally expressed A and C subunits, there is a pleth-
ora of B subunits with different expression patterns (1). The dif-
ferential substrate preferences of the nearly 100 different PP2A 
holoenzymes that, in theory, can be formed by 2 C isoforms, 2 A 
isoforms, and at least 23 types of B subunits is largely unknown (2), 
particularly within the context of a whole organism. Apparently, 
PP2A-dependent protein dephosphorylation has a potential for 
regulation that may be just as fine-tuned as protein phosphoryla-
tion. Unlike protein phosphorylation, associations between muta-
tions in PP2A subunits and genetic diseases or syndromes have 
not been described until recently, when 4 de novo PPP2R5D and 
3 de novo PPP2R1A mutations were found among the first 1,133 
parent-child trios sequenced in the United Kingdom Deciphering 
Developmental Disorders project (3).
Here, we add clinical descriptions and functional data to the 
DDD findings and present 9 additional cases with de novo PP2A 
subunit mutations; 7 in PPP2R5D, encoding the regulatory B56δ 
subunit, and 2 in PPP2R1A, encoding the scaffolding Aα subunit. 
Here we report inherited dysregulation of protein phosphatase activity as a cause of intellectual disability (ID). De novo 
missense mutations in 2 subunits of serine/threonine (Ser/Thr) protein phosphatase 2A (PP2A) were identified in 16 
individuals with mild to severe ID, long-lasting hypotonia, epileptic susceptibility, frontal bossing, mild hypertelorism, and 
downslanting palpebral fissures. PP2A comprises catalytic (C), scaffolding (A), and regulatory (B) subunits that determine 
subcellular anchoring, substrate specificity, and physiological function. Ten patients had mutations within a highly conserved 
acidic loop of the PPP2R5D-encoded B56δ regulatory subunit, with the same E198K mutation present in 6 individuals. Five 
patients had mutations in the PPP2R1A-encoded scaffolding Aα subunit, with the same R182W mutation in 3 individuals. 
Some Aα cases presented with large ventricles, causing macrocephaly and hydrocephalus suspicion, and all cases exhibited 
partial or complete corpus callosum agenesis. Functional evaluation revealed that mutant A and B subunits were stable and 
uncoupled from phosphatase activity. Mutant B56δ was A and C binding–deficient, while mutant Aα subunits bound B56δ 
well but were unable to bind C or bound a catalytically impaired C, suggesting a dominant-negative effect where mutant 
subunits hinder dephosphorylation of B56δ-anchored substrates. Moreover, mutant subunit overexpression resulted in 
hyperphosphorylation of GSK3β, a B56δ-regulated substrate. This effect was in line with clinical observations, supporting a 
correlation between the ID degree and biochemical disturbance.
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tures is, in itself, evidence in support of causality, especially when 
supported by functional data (see below). As a crude estimation, 
the likelihood of finding 10 de novo missense mutations in the 
same 9–amino acid stretch of B56δ by chance should be less than 
10–50 (see Statistics).
The clinical features of the 11 PPP2R5D cases and the 5 
PPP2R1A cases are summarized in Tables 2 and 3, respectively. 
Despite mutations occurring in 2 different PP2A subunit genes 
with different biochemical functions (regulatory and scaffolding), 
there are clinical similarities between the cases. All patients were 
born after a normal pregnancy, and 15/16 cases had birth weights 
within normal range. In 2 cases, breech deliveries were reported, 
and in 2 other cases, emergency cesarean sections had to be per-
formed. After birth, ID and hypotonia were common features in 
all cases. Despite pronounced and long-lasting hypotonia, feeding 
difficulties were usually not a major problem, and only one case 
had gastrostomy. In 12/16 cases, the degree of ID was severe, and 
this correlated with very late independent walking, usually around 
age 6–7 years. The exceptions were the 4 patients with E200K, 
P201R, or W207R PPP2R5D mutations (see below for functional 
explanation), who learned to walk between 1½ and 2¼ years of 
age and had mild/moderate ID (Table 2). These 4 cases were also 
the only ones with language development beyond a few words. 
Seven out of 16 patients had epilepsy, including one of the mild ID 
cases. Only one patient had short stature (case 1 with a P53S muta-
tion, see Table 2), and he was the only PPP2R5D case that was 
microcephalic. In the other PPP2R5D cases, head circumferences 
were from upper-normal range to pronounced macrocephaly, and 
in the latter cases, hydrocephalus was suspected. In contrast, most 
PPP2R1A cases were normocephalic or microcephalic, and hydro-
cephalus was initially suspected in only one case (Table 3). In all 
these patients, the corpus callosum was absent or almost absent, a 
feature that distinguished PPP2R1A cases from PPP2R5D cases. In 
contrast, facial features were overlapping (Figure 1): A hypotonic 
and sometimes also elongated face with tented upper lip, mild 
hypertelorism with downslanting palpebral fissures, and frontal 
bossing in the PPP2R5D cases.
The finding of recurrent and clustered de novo missense 
mutations in 2 PP2A subunit genes (PPP2R5D and PPP2R1A) sug-
gested a dominant-negative– or gain-of-function–related disease 
mechanism, rather than haploinsufficiency or loss-of-function. 
All but one of the PPP2R5D mutations (E198K, E200K, P201R, 
Taken together, of the 11 mutations in PPP2R5D, 6 mutations 
and 2 mutations were identical; 3 of the 5 mutations in PPP2R1A 
were also identical. All Aα mutations and all but one of the B56δ 
mutations had the potential to hinder access of catalytically com-
petent C subunits to B56δ-regulated substrates, suggesting a com-
mon dominant-negative disease mechanism mainly affecting 
B56δ-regulated Ser/Thr dephosphorylation.
Results
In cases with intellectual disability (ID) of unknown etiology, 
parent-child trio exome sequencing was performed to find de 
novo and recessive mutations that could explain the condition. 
De novo missense mutations in 2 subunits of the Ser/Thr phos-
phatase PP2A were identified in 16 individuals from the United 
Kingdom (7 cases), the Netherlands (7 cases), Israel (1 case), and 
Norway (1 case).
The 7 United Kingdom cases were found among 1,133 chro-
mosomally normal parent-child trios (3). This suggests that the 
prevalence of PP2A subunit mutations in the moderate-to-severe 
ID group without pathogenic copy number aberrations is around 
0.6%. In the United Kingdom, this was part of the large DDD proj-
ect (http://www.ddduk.org); in other cases, this was done as part 
of routine diagnostics. In 11 cases, de novo missense mutations 
in PPP2R5D, encoding the regulatory B56δ PP2A subunit, were 
found. In 5 other cases, a de novo missense mutation in PPP2R1A, 
encoding the scaffolding Aα subunit of PP2A, was found. Six 
mutations and 2 mutations in PPP2R5D were identical, and 3 
PPP2R1A mutations were identical. Details on all mutations can 
be found in Table 1. Other trio exome sequencing results indicat-
ing a de novo change of possible relevance or a recessive condition 
of potential interest can be found in Supplemental Table 1 (sup-
plemental material available online with this article; doi:10.1172/
JCI79860DS1). In 10 cases, such findings were made, but based 
on bioinformatic evaluation of the variants and the clinical fea-
tures of the patients, all but one of these findings could easily 
be excluded as causative factors for the phenotype. The excep-
tion was case 15, which had  heterozygocity for a TMEM67 splice 
mutation and a few signs that were compatible with a ciliopathy 
(e.g., unilateral postaxial polydactyly). However, this could also 
be a random finding, since a second TMEM67 mutation was not 
found upon Sanger sequencing. In addition, detecting the same 
de novo missense mutations in patients with identical clinical fea-
Table 1. De novo mutation details and the corresponding cases
Cases Gene Genomic changeA cDNA changeB Protein change
1 PPP2R5D chr6:g.42974253C>T c.157C>T p.Pro53Ser
2–7 PPP2R5D chr6:g.42975003G>A c.592G>A p.Glu198Lys
8–9 PPP2R5D chr6:g.42975009G>A c.598G>A p.Glu200Lys
10 PPP2R5D chr6:g.42975013C>G c.602C>G p.Pro201Arg
11 PPP2R5D chr6:g.42975030T>A c.619T>A p.Trp207Arg
12 PPP2R1A chr19:g.52715971C>T c.536C>T p.Pro179Leu
13–15 PPP2R1A chr19:g.52715979C>T c.544C>T p.Arg182Trp
16 PPP2R1A chr19:g.52716329G>A c.773G>A p.Arg258His
AGenomic positions are according to Build37/hg19. BcDNA reference sequences: NM_006245.2 for PPP2R5D and NM_014225.5 for PPP2R1A.
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further strengthening our working hypothesis that a charge 
change in the acidic B56δ loop could be pathogenic.
Our cellular binding assays with Glutathione S-Transferase– 
tagged (GST-tagged) B subunits and HemAgglutinin-tagged 
(HA-tagged) WT or mutant Aα subunits revealed that all 3 PPP2R1A 
mutations also affected PP2A holoenzyme formation (Figure 3). 
Surprisingly, interaction with the C subunit was hindered, despite 
the Aα mutations being in HEAT domains predicted to interact with 
B (Figure 3A). The mutations’ effect on B subunit binding was com-
plex (Figure 3B). All Aα mutants lacked significant binding to the B55 
(also called B) family members tested (isoforms B55α and B55β), as 
well as to the B56 (also called B’ or PR61) family members tested 
(B56α and B56γ). On the other hand, binding to B56δ was almost 
entirely retained, whereas B56ε bound significantly less. For PR72, 
a member of the B’’ family of PP2A regulatory subunits, binding was 
retained to Aα-P179L but was completely lost to the Aα-R182W and 
Aα-R258H mutants (Figure 3B). These (mutant) Aα binding charac-
teristics were confirmed for endogenous B55α and B56δ subunits, 
for which good-quality, isoform-specific antibodies are available 
(Figure 4A). These data could be compatible with a dominant- 
negative effect on, notably, B56δ for all Aα mutants, and on PR72 
and W207R) clustered in a highly conserved acidic loop that faces 
the A and C subunits (4–6). This acidic surface corresponds to the 
extended loop between α-helices 3 and 4 of HEAT domain 2 in the 
crystal structure of the highly related B56γ isoform (Figure 2A). 
Only the P53S mutation (case 1 in Table 2) localized outside this 
loop, i.e., in the B56δ-specific N-terminal domain.
To investigate if the PPP2R5D missense mutations affected 
subunit interactions, a human embryonic kidney cell line — 
HEK293 cells, a well-known model from previous PP2A subunit 
interaction studies (7) — was transfected with EGFP-tagged WT 
or mutant B56δ subunits in order to study subunit interactions. 
All ID-associated B56δ mutants except P53S showed deficient 
holoenzyme formation, i.e., A- or C-to-B56δ association (Fig-
ure 2B). To check if others had discovered missense variants 
in the same acidic B56δ loop, Broad institute’s ExAC browser 
(http://exac.broadinstitute.org/) was consulted. Only 2 other 
missense variants (P196L and P201S) were reported. Interest-
ingly, the latter variant was in the same residue as the de novo 
mutation (P201R) in case 10, although the amino acid change 
was different. Unlike P201R, we found that P201S failed to show 
any significant A or C binding defects (Supplemental Figure 1), 
Figure 1. Facial photographs. 
The display shows the facial 
features of the PPP2R5D cases 
that consented to facial pho-
tographs being shown and the 
PPP2R1A cases.
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problems expressing ID-associated B56δ subunits in cells (Fig-
ures 2–4). Furthermore, protein-synthesis–blocking experiments 
showed that the ID-associated B56δ (P53S, E198K) or Aα (P179L, 
R182W) mutants tested appeared more long-lived than the WT 
subunits in our assay (Supplemental Figure 2).
Taken together, for all but one (P53S in PPP2R5D) of the de 
novo mutations identified, our biochemical data are consistent with 
a common defect in PP2A-B56δ–dependent dephosphorylation. 
A-C binding–defective B56δ mutants, or C binding– but not B56δ 
binding–defective Aα-mutants, and B56δ binding Aα-mutants har-
boring a catalytically impaired C subunit, may all block dephospho-
rylation of PP2A-B56–specific substrates and interfere with phos-
phorylation-dephosphorylation dynamics in the brain. In line with 
this hypothesis, overexpression of the E198K B56δ mutant or the 
R182W Aα mutant in HEK293 cells resulted in increased phospho-
rylation of GSK-3β Ser9, an established PP2A-B56δ substrate in this 
cell line (Figure 5 and ref. 10).
Discussion
The presented work demonstrates that de novo missense mutations 
in genes encoding PP2A subunits may cause syndromic ID — and 
for Aα-P179L, provided that C binding would be lost or dimin-
ished in the B56δ-Aα mutant complex. To provide direct evidence 
that mutant Aα can complex with B56δ without C, we expressed 
HA-Aα mutants or HA-Aα (WT) in HEK293 cells stably expressing 
EGFP-TEV-B56δ (WT) and analyzed the presence of endogenous C 
in anti-HA immunoprecipitates from the tobacco etch virus–cleaved 
(TEV-cleaved) eluates of GFP-trapped B56δ (Figure 4B). While C 
subunit was clearly present in B56δ-Aα (WT) complex (as expected 
from normal holoenzyme formation), it was barely detectable in 
the B56δ-Aα-P179L complex, indicating that mutant Aα-P179L may 
bind B56δ but not C. In contrast, the B56δ-Aα-R182W and B56δ- 
Aα-R258H complexes still bound a significant amount of C (Figure 
4B). However, measurements of specific PP2A activity in these sam-
ples showed a decrease in phosphatase activity for all Aα mutants 
compared with WT (Figure 4C), suggesting that the C subunit pres-
ent in these B56δ-mutant A-C complexes is catalytically impaired.
Because previous reports had indicated increased B56δ sub-
unit degradation upon gradual reduction of A subunit levels (8, 9), 
we examined the stability of our mutant subunits, since unstable 
mutant proteins would preclude the interpretation of our func-
tional data. In line with our hypothesis, we did not experience any 
Table 2. Clinical features in cases with de novo PPP2R5D missense mutations
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Case 10 Case 11
Mutation P53S E198K E198K E198K E198K E198K E198K E200K E200K P201R W207R
Age of 
examination
53 yr 5 yr 11 yr 10 yr 15 yr 13 yr 2 yr 20 yr 4 yr 3 yr 9 yr
Sex Male Female Male Female Male Male Female Female Female Female Female
Delivery Normal Breech Normal Emergency C/S Emergency C/S Normal Amniotic 
rupture
C/S Normal Breech Normal
Birth weight Normal Normal Normal Normal Normal SGA Normal Normal Normal Normal Normal
Hypotonia Not 
reported
Present Present Present Present Present Present Present Present Present Present
Walked 
unsupported
9 yr 6 yr 6 yr Not so far 7 yr 6 yr Not so far 1½ yr 2¼ yr 1½ yr 2 yr
Ataxic gait No Yes Yes N/A No Yes N/A No Yes Yes No
Language No words 3–4  
words
No words 2 words, poor 
articulation
No words No words No words Yes, poor 
intelligibility
A few words A few words Yes, poor 
intelligibility
Epilepsy No No No No Multifocal Yes No No No Multifocal No
EEG – Abnormal – Normal Abnormal Abnormal Normal Normal Not done Abnormal Normal
ID/DD Severe Severe Severe Severe Severe Severe Severe Mild Mild Moderate Moderate
Height 0.5 cm 
< 3rd
10th 5th 25th 20 cm < 3rd 50th 90th 5–10th 50th 50th 50th
Head 
circumference
1 cm < 3rd 5 cm > 97th 50th 5 cm > 97th at 
age 3½ yr
50th 97th 99th 97th 1 cm > 97th 75th 97th
Weight Normal Normal 50th 90th 50th 90th 30th 10 kg > 97th 75th 60th 50th
Brain MRI – Pseudo-
hydroceph





Normal – Normal – Normal






















Height, head circumference, and weight are measured relative to centiles (the 3rd and 97th centile correspond to ± 2 SD). Abbreviations: ID/DD, intellectual 
disability/developmental delay; y, years; -, unknown or not done; SGA, small for gestational age; C/S, cesarean section; CC, corpus callosum.
Downloaded from http://www.jci.org on March 21, 2016.   http://dx.doi.org/10.1172/JCI79860
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
3 0 5 5jci.org   Volume 125   Number 8   August 2015
Besides its scaffolding function, Aα is a major player in the 
biogenesis of active PP2A holoenzymes (14). This highly regulated 
but incompletely understood process does not only involve simple 
trimeric assembly of the A, B, and C subunits, but it also involves 
several activation steps of the C subunit, which is de novo trans-
lated as an inactive enzyme (15). It has been suggested that some 
of these activation steps require or are facilitated by the A subunit 
(16, 17), explaining why A-subunit mutations may affect the spe-
cific activity of the associated C subunit, as observed here within 
the B56δ-(mutant A)-C complexes (Figure 4C). Additional activity 
measurements performed directly in anti-HA immunoprecipitates 
of HA-tagged (mutated) A subunits seem to further confirm this 
hypothesis (Supplemental Figure 3). Hence, it can be further ratio-
nalized why mutations in the A subunit have a much more severe 
effect on the PP2A system as a whole, as opposed to mutations in 
B56δ, which affect a single PP2A holoenzyme complex.
PPP2R5D encodes the longest isoform of the B’ family of 
PP2A regulatory subunits and harbors unique N- and C-terminal 
extensions, which are predicted to be important for substrate rec-
ognition and/or subcellular targeting (18). Ten out of 11 PPP2R5D 
mutations were located in a conserved acidic loop of B56δ needed 
for holoenzyme formation (Table 1), and all mutations introduced 
a positively charged residue (either arginine or lysine). Only one 
mutation (P53S) was atypical, and this case also had a different 
clinical picture: it was the only PPP2R5D case with short stature 
and microcephaly (Table 2). In theory, P53S in the B56δ-specific 
N-terminal domain might change the PP2A-B56δ interaction with 
relevant substrates or introduce a new phosphorylation site that 
affects regulation by protein kinases. Such changes could easily 
have a gain-of-function or dominant-negative effect.
We also observed a correlation between the degree of bio-
chemical disturbance and clinical severity. Among the PPP2R5D 
cases (Table 2), the 6 patients with E198K mutations were the 
most severely affected, in line with a near absence of A and C 
subunit binding. The least-affected individuals were the E200K 
cases, both with mild ID correlating with some residual A and C 
binding capability (Figure 2B). Notably, E198 is the only one of the 
5 mutated residues that directly interacts with the catalytic sub-
unit (Figure 2A and refs. 4–6). Additionally, since all B subunits, 
probably also nonsyndromic ID, since the facial dysmorphism in 
these cases is subtle (Figure 1). The PPP2R5D and PPP2R1A muta-
tions disrupt B56δ-dependent dephosphorylation dynamics and 
link PP2A dysfunction to congenital brain dysfunction.
In general, the Aα cases were more severely affected than the 
B56δ cases. All had severe ID, absent speech, diminished brain 
growth, and partial or complete agenesis of the corpus callosum 
(Table 3). This is in line with the expected greater difficulty to 
compensate for a general scaffolding (A) subunit dysfunction 
than a specific regulatory (B) subunit dysfunction, as reflected 
by our biochemical data showing additional loss or reduction of 
holoenzyme assembly of many different PP2A complexes (B55α, 
B55β, B56α, B56γ, and B56ε) for these Aα mutants (Figure 3B). 
The Aα scaffolding subunit is highly flexible, composed of 15 
tandem repeat HEAT motifs (11) that mediate interactions with 
a regulatory B subunit (HEAT repeats 1–8) and the C subunit 
(HEAT repeats 11–15)(4, 5, 12, 13). Two ID-associated PPP2R1A 
mutations (P179L and R182W) cluster in HEAT domain 5 of Aα, 
and one (R258H) occurs in HEAT domain 7; these mutations are 
involved in contacts with subunits of all B families (4, 5, 12, 13). 
However, for these mutations, loss-of-function might be less 
critical than substrate protection and altered phosphorylation 
dynamics; hence, the retained binding to PR72 for Aα-P179L 
could have additional functional consequences due to seques-
tration of PR72 in a complex deficient in C subunit binding or 
with decreased specific activity of C.
Figure 2. Binding of mutant and WT B56δ to the A or C subunits. (A) 
Model of the highly conserved B56 acidic loop, harboring 4 ID-associ-
ated B56δ missense mutations, based on crystallographic data from 
PP2A-B56γ (PDB code: 2IAE)(5). The corresponding residues in B56γ 
(highlighted in white) are displayed with amino acid numbering accord-
ing to B56δ. Note that the E198 residue directly contacts the C subunit. 
Color code: C subunit, blue; A subunit, yellow; B56γ, red. The structure 
was analyzed and visualized with Molsoft MolBrowser 3.7. (B) Cellular 
binding assays of ID-associated B56δ mutants and endogenous A and C 
subunits. EGFP-tagged WT B56δ, 5 ID-associated B56δ mutants (P53S, 
E198K, E200K, P201R, and W207R), or EGFP alone (–) were ectopically 
expressed in HEK293 cells. Following EGFP trapping, the presence of 
endogenous A and C subunits in the trapped complexes was examined 
by immunoblotting (IB). After quantification of the band intensities 
with ImageJ software, the ratios between EGFP and C signals — and 
between EGFP and A signals — were determined and calculated relative 
to B56δ WT control. Mean values and a representative image of 4 inde-
pendent experiments are shown (1-way multiple-comparisons ANOVA; 
*P < 0.05, **P < 0.01).
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except B56δ and PR72, have been shown to make stabilizing con-
tacts with the C subunit tail (5, 19), C-subunit binding to B56δ, and 
possibly PR72, may be particularly Aα dependent.
A brain-restricted phenotype is not unexpected for B56δ 
mutations because PPP2R5D is expressed mainly in the brain, 
particularly in the striatum (18, 20, 21). The brain-restricted phe-
notype of the Aα mutations (P179L, R182W, and R258H) is more 
unexpected, since PPP2R1A is generally expressed as a common 
scaffolding subunit for many different PP2A holoenzymes (22). 
Nevertheless, other malformations than severe corpus callosum 
hypogenesis were not found in the 5 PPP2R1A cases (Table 3). The 
restricted phenotype may be related to our finding that mutated 
A subunits bound most tightly to B56δ and (for P179L) also PR72 
(Figure 3B), both of which are expressed in the brain, notably in 
the striatum where both B56δ and PR72 (encoded by PPP2R3A) 
control the dephosphorylation of the neural dopamine-regulated 
inhibitor of PP1 (DARPP-32) (23–25).
Despite the severe intellectual dysfunction in most patients, 
B56δ does not appear essential for mammalian brain develop-
ment, since Ppp2r5d knockout mice have intact learning and mem-
ory despite ataxia and tauopathy (21). This also suggests that our 
patients’ ID was not caused by haploinsufficiency or a mere loss 
of function. It is therefore tempting to speculate that the mutated 
B56δ subunits may not only interfere in a dominant manner with 
dephosphorylation of B56δ binding PP2A substrates, as shown 
for GSK-3β in HEK293 cells (Figure 5), but also with subcellular 
anchoring of PP2A via B56δ, and thereby with control of localized 
signaling. Thus, A-C binding–deficient B56δ mutants may still form 
complexes with B56δ partners, but without promoting dephos-
phorylation. Such dysphosphorylation may have far-reaching 
consequences for regulation of localized signaling. One exam-
ple could be the signaling complex scaffolded by the neural vari-
ant of the cAMP-dependent PKA anchoring protein mAKAP, 
that binds B56δ and several other phosphatases (PP1, PP2B) and 
kinases (PKA, PDK1, RSK3, ERK5) (26, 27). Dephosphorylation of 
PP2A-B56 substrates may also be hindered, e.g., the transcription 
factor and PKA-substrate HAND (28), the neural cyclin-depen-
dent kinase 5 (CDK5) activator CDK5R1 (21), and DARPP-32 (24, 
25). PKA activates DARPP-32 directly by Thr-34 phosphorylation 
and indirectly by PP2A-B56δ–dependent activation through Thr-
75 dephosphorylation (24). B56δ has several sites for PKA phos-
phorylation that activate PP2A-B56δ phosphatase activity (24, 29). 
Moreover, PKA-activated PP2A-B56δ–dependent dephosphoryla-
tion of another DARPP-32 phosphorylation site (Ser-97) induces 
nuclear import — mediating dopamine-dependent epigenetic 
functions (25) — and lack of nuclear PP2A-B56δ targeting has 
been associated with juvenile myoclonic epilepsy (30). There is 
also evidence that PP2A-B56δ regulates both expression (30) and 
activity (31) of tyrosine hydroxylase, the rate-limiting enzyme in 
catecholamine synthesis. Which of these candidate substrates will 
eventually be of pathologic relevance in our ID patients remains to 
be further determined in appropriate cellular and animal models.
A model for a common dominant-negative effect of mutant 
B56δ and Aα subunits is depicted in Figure 6. This model explains 
why all our biochemical findings are compatible with B56δ- 
dependent PP2A dysregulation. Our model is also supported 
by a recent paper showing that Aα can form a tight complex in 
vitro with members of the B’’ subunit family, including PR72, in 
Table 3. Clinical features in cases with de novo PPP2R1A missense mutations
Case 12 Case 13 Case 14 Case 15 Case 16
Mutation P179L R182W R182W R182W R258H
Age of examination 3½ yr 4 yr 11 yr 1 yr 5 yr
Sex Female Female Male Female Male
Delivery Normal Normal Normal Labor-induced (hydrocephalus) Normal
Birth weight Normal Normal Normal Normal Normal
Hypotonia Present Present Present Present Present
Walked unsupported Not so far Not so far 6 yr  Not so far 3 yr
Ataxic gait N/A N/A Yes N/A Yes
Language No words No words No words No words ~30 words
Epilepsy No Yes Yes, multifocal Yes Yes
EEG – Abnormal Abnormal Abnormal Abnormal
ID Severe Severe Severe Severe Severe
Height ~90th ~97th 50th 75th 90th
Head circumference 2 cm < 3rd 10th 2nd 98th > 75th 1 cm < 2nd
Weight 75th 97th 10th 16th 97th
Brain MRI CC agenesis CC hypoplasia  
Large ventricles
CC hypoplasia CC agenesis  
Delayed myelinisation  
Large ventricles
CC hypoplasia  
Delayed myelinisation
Other findings Cortical visual 
impairment
Scoliosis Scoliosis Hip dysplasia 
Hypermobility  
Physically strong 
Gastrostomy age 8 yr
Cortical visual impairment 
Unilateral postaxial polydactyly 
Unilateral kidney agenesis 




Height, head circumference, and weight are given relative to centiles (the 3rd and 97th centile correspond to ± 2 SD). Abbreviations: y, years; CC, corpus 
callosum; C/S, cesarean section; –, unknown or not done.
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Figure 3. Binding of mutant and WT Aα to C and B subunits. (A) PP2A-C subunit binding assays: HA-tagged WT Aα, 3 ID-associated Aα mutants (P179L, 
R182W, and R258H), or an empty HA-vector (–) were transfected into HEK293 cells. Following anti-HA immunoprecipitation, the presence of endoge-
nous C subunit in the immunoprecipitates was examined by immunoblotting (IB). After quantification of the band intensities with ImageJ software, the 
ratios between HA and C signals were determined and calculated relative to WT Aα control. Mean values and a representative image of 3 independent 
experiments are shown (1-way multiple-comparisons ANOVA, **P < 0.01). (B) PP2A B subunit binding assays: Several GST-tagged B subunits, belonging 
to 3 different families (B55 or B, B56 or B’, and B’’) or GST alone (–) were coexpressed in HEK293 cells with HA-tagged WT Aα, or ID-associated Aα-P179L, 
R182W, and R258H mutants. The presence of HA-Aα (WT or mutant) in the complete lysates and the isolated GST pulldown complexes was determined 
by IB. After quantification of the band intensities with ImageJ software, the ratios between GST and HA signals were determined and calculated relative 
to WT Aα control (which were set to 100% for each B-type subunit pulldown). Mean values and a representative image of 3 independent experiments are 
shown (1-way multiple-comparisons ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001).
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the most prevalent mutations. A growth 
advantage may also explain mutation 
recurrence if these de novo mutations 
turn out to be solely paternal (40). Since 
88% of the cancer-associated Aα muta-
tions are of the missense-variant, a 
dominant-negative effect also in cancer 
promotion is likely. None of our patients 
have been diagnosed with or treated for 
cancer. The cancer risk might not be 
increased, in line with what is usually 
the case for congenital gain-of-func-
tion mutations in other cancer-related 
pathways like the RAS/MAPK pathway 
or the PI3K/AKT cascade. Only further 
patients and patient follow-ups will 
answer this question, but a major cancer 
risk seems unlikely.
The tumor-suppressor effect of 
PP2A may operate by KRAS/MAPK 
cascade inhibition, KRAS/ARF/TP53 
cascade inhibition, or PI3K/AKT/TP53 
cascade inhibition (33). Somatic mosaic 
activation of the PI3K/AKT cascade 




group of overgrowth syndromes (41). 
These patients have variable ID, a ten-
dency to develop hydrocephalus and 
epilepsy, and dysmorphic facial fea-
tures, including frontal bossing with 
hypotonia, tented upper lip, and deep-
set eyes. The latter features are shared 
with several of our patients (Figure 1). It 
is therefore relevant to consider B56δ- 
dependent PP2A dysregulation syn-
drome (which we propose to be desig-
nated B56deltopathies) among the dif-
ferential diagnoses to the MCAP/MPPH 
group of syndromes, at least in some 
cases. It is conceivable that the B56δ 
mutations may affect only a subgroup 
of PP2A substrates located distally in 
the PIK3 signaling cascade — such as GSK-3β Ser9, a well-estab-
lished Akt phosphorylation site — since the proximal steps do not 
appear to be subject to B56δ-dependent dephosphorylation (42).
In summary, we have demonstrated that de novo missense 
mutations in the PPP2R5D and PPP2R1A genes encoding PP2A 
subunits represent a new mechanism for ID, due to disrupted B56δ- 
dependent dephosphorylation dynamics and PP2A dysfunction.
Methods
Case detection. There were 7 Dutch patients (from RUMC: cases 1, 
8–9, and 11; from UMC Utrecht: cases 7, 15, and 16). Six of these 
cases were identified through routine diagnostic exome sequencing 
the absence of the C subunit (32). It may be of interest to study 
if fingolimod (FTY720), a PP2A activator and immunosuppres-
sant that is licensed for treatment of multiple sclerosis (33–35), or 
FDA-approved compounds of the phenothiazine family that were 
recently discovered as PP2A activators (36) may improve brain 
function in these patients.
For future evaluation of de novo mutation origin (paternal 
or maternal)(37), it is of interest that all 3 PPP2R1A mutations 
also are found in the Sanger Institute’s Catalogue of Somatic 
Mutations in Cancer (the COSMIC database; http://cancer.
sanger.ac.uk/cosmic), mainly in endometrial and ovarian can-
cers (38, 39). Aα P179L/P179R, R182W, and R258H are by far 
Figure 4. Analysis of Aα mutant complexes. (A) Endogenous B subunit binding assays: HA-tagged WT 
Aα, Aα mutants (P179L, R182W, and R258H), or an empty HA-vector (–) were transfected into HEK293 
cells. Following anti-HA immunoprecipitation, presence of endogenous B56δ and B55α subunits in the 
immunoprecipitates was examined by immunoblotting (IB). (B) Formation of B56δ-(mutant Aα)-C com-
plexes: HEK293 cells stably expressing EGFP-TEV-B56δ were transfected with HA-Aα, HA-Aα mutants, 
or empty HA-vector (–). Following EGFP-trapping and cleavage of the trapped complexes with TEV pro-
tease, the eluates were subjected to HA immunoprecipitation and the immunoprecipitates analyzed by 
IB with anti-HA, anti-C, and anti-B56δ antibodies. After quantification of the band intensities (ImageJ), 
the ratios between C and HA signals were determined and calculated relative to WT Aα control (set to 
100% in each IP-on-IP experiment). Mean values and a representative image of 4 independent experi-
ments are shown (1-way multiple-comparisons ANOVA; *P < 0.05). (C) PP2A activity measurements in 
B56δ-(mutant Aα)-C complexes. The pmol number of released phosphate from K-R-pT-I-R-R phospho-
peptide (350 μM) was determined by Malachite Green for each B56δ-(mutant Aα)-C complex (retrieved 
as in B). To obtain specific C activities, this number was divided by the amount of C in the respective 
samples, as determined by IB and following quantification by ImageJ software. All specific activities 
were eventually recalculated relative to WT Aα control (set to 100%). Mean values and one representa-
tive image of 3 independent experiments are shown (1-way multiple-comparisons ANOVA; **P < 0.01).
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variations (CNVs) in the child, and exome sequencing to investi-
gate single nucleotide polymorphisms (SNPs) and small insertions/
deletions (indels). Putative de novo sequence variants were vali-
dated using targeted Sanger sequencing of blood-sample DNA. All 
genomic variants were annotated with the most severe consequence 
predicted by Ensembl Variant Effect Predictor (VEP) (45) and their 
minor allele frequencies observed in diverse population samples. 
Likely, diagnostic variants were fed back to referring clinical genet-
icists for validation and discussion with the family via the patient’s 
record in Database of Chromosomal Imbalance and Phenotype in 
Humans Using Ensembl Resources (DECIPHER; Ensembl) (46), 
where they can be viewed in an interactive genome browser. Full 
genomic datasets were also deposited under accession number 
EGAS00001000775 in the European Genome-Phenome Archive 
(www.ebi.ac.uk/ega).
The de novo PPP2R5D mutations in the Norwegian (case 2) and 
Israeli (case 6) patients were identified by exome sequencing of 
parent-child trios in a diagnostic setting. Only the PPP2R5D variant 
remained as true de novo after filtering and verification by Sanger 
sequencing of blood DNA, and no pathogenic copy number changes 
were detected by a high-resolution copy number array.
Biochemical investigations. To study the functional consequences 
of the de novo missense mutations, WT Aα and B56δ (isoform 1) 
cDNAs were cloned into HA-tag (pMB001) and EGFP-tag (pEGF-
P-C1) eukaryotic expression vectors, respectively. The different PP2A 
B-subunit cDNAs were in a GST-tag eukaryotic expression vector, as 
described (19). PCR-based site-directed mutagenesis (Stratagene) 
was performed directly in the pMB001 or pEGFP vectors with proof-
of patient-parent trios. These patients showed no pathogenic copy 
number changes (high-resolution copy number array). Putative de 
novo variants were validated by Sanger sequencing of blood DNA. 
In 4 of 7 cases, other de novo variants were identified, but none of 
these were likely to cause the phenotype (Supplemental Table 1). A 
possible exception was case 16, in which heterozygosity for a likely 
pathogenic mutation in the TMEM67 was identified. The patient 
had clinical features partly consistent with a ciliopathy (unilateral 
postaxial polydactyly, unilateral kidney agenesis, and absent uterus). 
However, a second TMEM67 mutation was not identified after 
Sanger sequencing. Cases 1 and 11 have been previously published 
as part of studies showing the power and impact of next-generation 
sequencing–based (NGS-based) technologies in a clinical diagnostic 
setting without clinical details on the patients’ phenotypes or func-
tional evaluation of the mutations (43, 44). Case 8 was identified as 
part of large-scale resequencing study of candidate ID genes using 
molecular inversion probes (MIPs). PPP2R5D was one of 42 candi-
date ID genes tested in 1,300 cases with a clinical diagnosis of ID and 
in whom previous molecular diagnostic tests were negative.
The 7 United Kingdom patients (cases 3–5, 10, and 12–14 in 
Tables 2 and 3) were recruited to the DDD study by the United King-
dom National Health Service or the Republic of Ireland Regional 
Genetics Service (3). Recruitment criteria were patients with neu-
rodevelopmental disorders and/or congenital anomalies, abnormal 
growth parameters, dysmorphic features, and unusual behavior. 
DNA samples from patients and parents were analyzed by the Well-
come Trust Sanger Institute using high-resolution microarray anal-
ysis (array-CGH and SNP-genotyping) to investigate copy number 
Figure 5. Increased phosphorylation of GSK-3β Ser9 upon expression of B56δ-E198K or Aα-R182W. GFP-tagged WT B56δ, E198K mutant B56δ, or GFP 
alone (–) (left); or HA-tagged WT Aα, R182W mutant Aα, or HA alone (–) (right) were expressed in HEK293 cells, and the effect on GSK-3β phosphorylation 
determined by immunoblotting (IB) with the indicated antibodies. Total GSK-3β and phospho-Ser9 GSK-3β signals were determined on different blots, 
which were both developed for vinculin to correct for loading differences. In cells expressing the ID-associated mutants, higher phospho/total GSK-3β 
ratios were found, relative to cells transfected with empty expression vector (in which case, this ratio was set to 100%) or cells expressing WT subunits. 
Mean values and one representative image of 3 independent experiments are shown (1-way multiple-comparisons ANOVA; *P < 0.05, **P < 0.01).
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4°C. The following primary antibodies were used: mouse monoclonal 
anti-GST (Sigma-Aldrich), anti-HA (Sigma-Aldrich), anti-GFP (Corn-
ing), anti–PP2A-A subunit (supplied by S. Dilworth, Middlesex Univer-
sity, London, United Kingdom), anti–PP2A-C subunit (BD Biosciences); 
and rabbit polyclonal anti-B55α (Cell Signaling Technology), and anti-
B56δ (20). After washing in TBS/0.1% Tween 20, the membranes were 
incubated at room temperature for 1 hour with horseradish peroxidase–
conjugated secondary antibodies (Dako) and developed using a Pierce 
enhanced chemiluminescence detection system (Thermo Fisher Scien-
tific). All densitometric quantifications were done with ImageJ software.
For the IP-on-IP approach, a polyclonal population of HEK293 
cells stably expressing EGFP-TEV-B56δ was used (selected with 
2 μg/ml puromycin). The EGFP-TEV expression vector was a gift of 
E. Heroes (KU Leuven, Leuven, Belgium). Forty-eight hours after 
transfection with HA-Aα (pMB001) or HA-mutant Aα (pMB001), 
EGFP trapping was performed, and the trapped complexes were 
incubated overnight at 4°C with 0.2 μg/μl of recombinant TEV 
protease in TEV cleavage buffer (TBS, 1 mM DTT, 0.5 mM EDTA). 
Following addition of EDTA (1 mM), PMSF (1 mM), and TLCK 
(1 mM), the TEV eluates were subjected to HA immunoprecipitation 
with HA-agarose beads and the washed immunoprecipitates were 
analyzed by immunoblotting with anti-HA, anti–PP2A-C, and anti-
B56δ antibodies (20, 21).
For PP2A activity measurements, the HA-agarose beads were 
washed once more with 20 mM Tris HCl pH 7.4 plus 1 mM DTT, and 
finally resuspended in 60 μl enzyme dilution buffer (catalog 20-169, 
Millipore). All assays were performed with 20 μl of this phosphatase 
suspension and 4.5 μl of 2 mM stock of K-R-pT-I-R-R phosphopeptide 
(catalog  12-219, Millipore) for 10–60 minutes at 30°C (still in the lin-
ear range of the assay). The released free phosphate was determined 
by the addition of malachite green solution (10/1 mix of solution A 
[catalog 20-105, Millipore] and solution B [catalog 20-104, Milli-
pore]). After 15 min incubation at room temperature, absorbance at 
630 nm was measured in a multi-channel spectrophotometer. Pico-
molar amounts of phosphate released were calculated by comparison 
with a standard curve of known KH2PO4 concentrations, as outlined 
in the manufacturer’s instructions (Ser/Thr Phosphatase Assay Kit 1, 
Millipore). Specific phosphatase activity was obtained by correcting 
reading Pwo polymerase (Roche Applied Science) and complemen-
tary DNA oligonucleotide primers (Sigma-Aldrich) containing the 
desired point mutations (primer sequences in Supplemental Table 2). 
All mutations were confirmed by sequencing (LGC Limited). There-
after, HEK293 cells (ATCC) were transfected with PEI transfection 
reagents according to standard protocol. Forty-eight hours after 
transfection, cells were rinsed with PBS, lysed in 200 μl NET buffer 
(50 mM Tris pH 7.4, 150 mM NaCl, 15 mM EDTA, and 1% Nonidet 
P-40) containing protease and phosphatase inhibitor cocktail (Roche 
Applied Science), and centrifuged for 15 minutes at 13,000 g. In case 
phosphatase activity needed to be measured, phosphatase inhibitors 
were omitted from the lysis buffer.
For EGFP trapping, cell lysates were incubated at 4°C for 1 hour 
with wash buffer (10 mM Tris-HCl pH 7.5, 0.5 mM EDTA, and 150 mM 
NaCl) and 15 μl GFP-trap-A beads (ChromoTek GmbH) on a rotating 
wheel. The beads were washed 4 times with 0.3 ml of wash buffer.
For GST pulldown, cell lysates were incubated at 4°C for 1 hour 
with NENT100 buffer (20 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.1% 
Nonidet P-40, 25% glycerol, and 100 mM NaCl) containing 1 mg/ml 
bovine serum albumin and 25 μl glutathione-Sepharose beads (GE 
Healthcare) on a rotating wheel. The beads were washed 2 times with 
0.3 ml of NENT100 containing 1 mg/ml bovine serum albumin, and 2 
times with 0.3 ml of NENT300 containing 300 mM NaCl.
For HA immunoprecipitation, the lysates were precleared with 
Protein A-Sepharose beads (GE Healthcare) for 1 hour, and incubated 
on a rotating wheel at 4°C for 2 hours with 1 μg HA antibody (Sig-
ma-Aldrich) in TBS/1% Nonidet P-40. Protein A-Sepharose beads 
were added for 1 hour, and beads were washed 2 times in NENT300 and 
2 times in TBS/0.1% Nonidet P-40. Alternatively, 25 μl HA-agarose 
beads (Sigma-Aldrich) were directly added to the lysates and incu-
bated on a rotating wheel in 500 μl TBS/0.1% Nonidet P-40 for 1.5 
hours at 4°C. Beads were washed 4 times in TBS/0.1% Nonidet P-40.
In all cases, bound proteins were eluted by the addition of NuPAGE 
sample buffer (Invitrogen) and boiling. The eluted proteins were sub-
sequently analyzed by SDS-PAGE on 4%–12% (wt/vol) Bis-Tris gels 
(Bio-Rad) and Western blotting. The membranes were blocked in 5% 
milk solution in TBS/0.1% Tween 20 for 1 hour at room temperature 
and subsequently incubated with the primary antibody overnight at 
Figure 6. Mechanistic model. Top panels model the physiological 
situation in which the B-type subunit dictates subcellular targeting, 
substrate specificity, and substrate dephosphorylation by the C subunit. 
Conceivably, certain B subunits (like B56δ) or A-B dimers could dock 
to substrates independent of holoenzymes (alternatives labeled with 
question marks). Bottom panel displays the pathological situation 
in which (i) a B subunit mutation hindering interaction of the A and 
C subunit, (ii) an A subunit mutation hindering interaction of the C 
subunit but not the B subunit, or (iii) an A subunit mutation resulting in 
the incorporation of a catalytically impaired C subunit into the trimeric 
complex result in protection of B subunit–directed substrate dephos-
phorylation by a competition-based, dominant-negative mechanism. 
The common feature in all ID cases described here is hindered access of 
the PP2A activity to B56δ-specific PP2A substrates. S, substrate;  
P, phosphate.
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ings. Written informed consent was also obtained for publication of 
all facial photographs presented in Figure 1.
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these absolute values for amount of C present in the samples, as 
determined by immunoblotting with anti-C antibodies and quantifi-
cation of the signals by ImageJ software.
For protein-stability analysis, HEK293 cells were transfected 
with EGFP-B56δ (WT); with EGFP-B56δ-P53S or EGFP-B56δ-
E198K mutants (pEGFP-C1); or with HA-Aα (WT), HA-Aα-R182W, 
or HA-Aα-P179L mutants (pMB001), one 10 cm plate per plasmid. 
Twenty-four hours after transfection, each 10-cm plate was split over 
6 wells on a 6-well plate, in which eventually 50 μM cycloheximide 
(CHX, Sigma-Aldrich) was added per well to block translation. Fol-
lowing incubation with CHX for different time points (0, 10, and 24 
hours), whole-cell lysates were prepared in NET lysis buffer and fur-
ther analyzed by immunoblotting with anti-vinculin mouse monoclo-
nals (Sigma-Aldrich), anti-HA, or anti-GFP antibodies. Band intensi-
ties were quantified using ImageJ software.
Statistics. Statistical analysis of biochemical data was done with 
1-way multiple-comparisons ANOVA, and P < 0.05 was considered to 
be significant.
The calculation of the chance likelihood for finding 10 de novo 
mutations in the same 9–amino acid stretch of B56δ was based on the 
following assumptions: The target size is <10–6 of the total ORF size, 
the number of random missense changes per generation is on average 
1, and the index is removed from the equation. This gives a chance 
likelihood of less than (10–6)9, or <10–54, not taking the lack of similar 
variants in ExAC into account. The chance of finding a similar vari-
ant in the whole ID dataset by chance is about 2 × 10–3, assuming that 
about 2,000 ID cases were tested. In that case, the phenotype should 
also be random, and this was not the case.
Study approval. The DDD study has UK Research Ethics Commit-
tee (REC) approval (10/H0305/83, granted by the Cambridge South 
REC, and GEN/284/12 granted by the Republic of Ireland REC). In 
other cases, ascertainment of patients was part of the clinical routine. 
All patients’ families have consented to publication of clinical find-
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